Contact us

877-469-1TRM
424-208-8866

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO).

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Refractory Indolent Non-Hodgkin Lymphoma IPI-145 II Open and Accruing